You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Eugia Pharma Speclts Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for EUGIA PHARMA SPECLTS, and what generic alternatives to EUGIA PHARMA SPECLTS drugs are available?

EUGIA PHARMA SPECLTS has eighteen approved drugs.

There is one US patent protecting EUGIA PHARMA SPECLTS drugs. There are two tentative approvals on EUGIA PHARMA SPECLTS drugs.

There are ten patent family members on EUGIA PHARMA SPECLTS drugs in nine countries and one supplementary protection certificate in one country.

Summary for Eugia Pharma Speclts
International Patents:10
US Patents:1
Tradenames:12
Ingredients:12
NDAs:18

Drugs and US Patents for Eugia Pharma Speclts

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eugia Pharma Speclts FLUOROURACIL fluorouracil INJECTABLE;INJECTION 202668-002 Jul 17, 2012 AP RX No No ⤷  Subscribe ⤷  Subscribe
Eugia Pharma Speclts DIPYRIDAMOLE dipyridamole INJECTABLE;INJECTION 075769-001 Nov 27, 2002 DISCN No No ⤷  Subscribe ⤷  Subscribe
Eugia Pharma Speclts AMPICILLIN AND SULBACTAM ampicillin sodium; sulbactam sodium INJECTABLE;INJECTION 090340-002 Sep 20, 2010 DISCN No No ⤷  Subscribe ⤷  Subscribe
Eugia Pharma Speclts METHOTREXATE SODIUM PRESERVATIVE FREE methotrexate sodium INJECTABLE;INJECTION 201529-003 Mar 29, 2012 DISCN No No ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Eugia Pharma Speclts Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0257344 SPC/GB98/043 United Kingdom ⤷  Subscribe PRODUCT NAME: DIPYRIDAMOLE, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, AND O-ACETYLSALICYLIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY SALT, I.E. ASASANTIN RETARD; REGISTERED: FR NL 22160 19970709; UK 00015/0224 19980512
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.